一家纽约律师公司正在调查针对多家公司的证券欺诈指控，原因是未披露的风险、失败的审判以及误导性言论，此前2024年底至2026年初股市大幅下跌。 A New York law firm is probing securities fraud claims against several companies over undisclosed risks, failed trials, and misleading statements, following sharp stock drops from late 2024 to early 2026.

一家设在纽约的法律事务所正在调查在与未披露的财务风险挂钩的股票急剧下降或临床试验失败后对多个公司提出的潜在的证券欺诈索赔。 A New York-based law firm is investigating potential securities fraud claims against multiple companies following sharp stock declines tied to undisclosed financial risks or failed clinical trials. 这些探测器涵盖2024年后期至2026年初的时期,涉及关于金融健康、违反安全规定、监管倒退和欺诈交易的误导性陈述的指控。 The probes cover periods from late 2024 to early 2026 and involve allegations of misleading statements about financial health, security breaches, regulatory setbacks, and fraudulent trading. 关键的触发因素包括Rezolute的药物试验失败,FDA对Aquestive的药物应用的担忧,Gauzy的破产程序,Ardent Health的会计调整,以及Smart Digital Group的市场操纵计划. Key triggers include a failed drug trial for Rezolute, FDA concerns over Aquestive’s drug application, insolvency proceedings at Gauzy, accounting adjustments at Ardent Health, and a market manipulation scheme at Smart Digital Group. 鼓励在特定时期遭受损失的投资者与公司联系,以便采取可能的法律行动,主要原告的起诉期限为2026年2月至3月。 Investors who suffered losses during specified periods are encouraged to contact the firm for potential legal action, with deadlines for lead plaintiff filings ranging from February to March 2026.